Lisa Bollinger, MD

Lisa Bollinger, MD has served as member of the board since May 2024 and is the Chief Medical Officer of Polaryx Therapeutics. Dr. Bollinger previously was the CEO and President of Bollinger Regulatory Consulting (BRC), LLC, and served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck. Prior to Merck, Dr. Bollinger spent nearly 10 years with Amgen, where she held roles across global regulatory affairs and safety, with a particular focus on pediatrics. In her most recent role at Amgen, Dr. Bollinger served as Vice President, Global Patient Safety & Pediatrics, and Labeling Global Regulatory Affairs & Safety (GRAAS), Research and Development. Before Amgen, she spent 12 years in various roles at the U.S. Food and Drug Administration, including within the Division of Pediatric Drug Development, the Office of Counterterrorism and the Center for Drug Evaluation and Research. For six years, she held the position of Associate Director, Office of New Drugs within CDER and oversaw the Pediatric and Maternal Health Staff. Earlier, Dr. Bollinger spent time as a staff pediatrician at several hospitals within the National Health Service Corp. She also served as an Adjunct Professor of Pediatrics at the Uniformed Services University of the Health Sciences and has published numerous books and publications. Dr. Bollinger holds an M.D. from the Uniformed Services University of the Health Sciences F. Edward Hebert School of Medicine and a B.S. in physiology from the University of California, Davis.